TY - JOUR
T1 - Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer
AU - Wisselink, Daan D
AU - Braakhuis, Linde L F
AU - Gallo, Gaetano
AU - van Grevenstein, Wilhelmina M U
AU - van Dieren, Susan
AU - Kok, Niels F M
AU - de Reuver, Philip R
AU - Tanis, Pieter J
AU - de Hingh, Ignace H J T
N1 - Funding Information:
Unrestricted scientific grant of the Dutch Cancer Society. The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/10
Y1 - 2019/10
N2 - BACKGROUND: The role of hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin in addition to cytoreductive surgery (CRS) has recently been questioned in peritoneal metastases of colorectal cancer. Whether this applies to all published CRS/HIPEC regimens is unclear.METHODS: A systematic literature search identified 46 studies on CRS/HIPEC using either oxaliplatin of mitomycin C with at least one oncological outcome parameter RESULTS: Oxaliplatin and mitomycin C studies were comparable regarding extent of disease, but differed substantially regarding synchronous versus metachronous presentation, application of neo-adjuvant systemic chemotherapy, duration of HIPEC, and completeness of cytoreduction for at least one of the oncological endpoints. Severe postoperative complication rate seemed significantly higher after oxaliplatin-based CRS/HIPEC.CONCLUSION: Published cohorts on oxaliplatin-based CRS/HIPEC differed essentially from MMC-based procedures, especially considering the application of oxaliplatin-containing neo-adjuvant systemic therapy and shorter exposure time to intraperitoneal chemotherapy in oxaliplatin studies. No meaningful comparison could be made regarding DFS and OS.
AB - BACKGROUND: The role of hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin in addition to cytoreductive surgery (CRS) has recently been questioned in peritoneal metastases of colorectal cancer. Whether this applies to all published CRS/HIPEC regimens is unclear.METHODS: A systematic literature search identified 46 studies on CRS/HIPEC using either oxaliplatin of mitomycin C with at least one oncological outcome parameter RESULTS: Oxaliplatin and mitomycin C studies were comparable regarding extent of disease, but differed substantially regarding synchronous versus metachronous presentation, application of neo-adjuvant systemic chemotherapy, duration of HIPEC, and completeness of cytoreduction for at least one of the oncological endpoints. Severe postoperative complication rate seemed significantly higher after oxaliplatin-based CRS/HIPEC.CONCLUSION: Published cohorts on oxaliplatin-based CRS/HIPEC differed essentially from MMC-based procedures, especially considering the application of oxaliplatin-containing neo-adjuvant systemic therapy and shorter exposure time to intraperitoneal chemotherapy in oxaliplatin studies. No meaningful comparison could be made regarding DFS and OS.
KW - Antineoplastic Agents/therapeutic use
KW - Colorectal Neoplasms/drug therapy
KW - Combined Modality Therapy
KW - Cytoreduction Surgical Procedures
KW - Humans
KW - Hyperthermia, Induced
KW - Mitomycin/therapeutic use
KW - Oxaliplatin/therapeutic use
KW - Peritoneal Neoplasms/drug therapy
KW - Cytoreductive surgery
KW - Colorectal cancer
KW - Survival
KW - Morbidity
KW - Oxaliplatin
KW - HIPEC
KW - Mitomycin C
KW - Peritoneal metastases
UR - http://www.scopus.com/inward/record.url?scp=85070191761&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2019.06.014
DO - 10.1016/j.critrevonc.2019.06.014
M3 - Review article
C2 - 31400583
SN - 1040-8428
VL - 142
SP - 119
EP - 129
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
ER -